Abstract
Several clinical trials have performed risk-benefit analyses comparing docetaxel and pemetrexed or docetaxel and vinca alkaloid, but the efficacy and safety remain uncertain. The aim was to conduct a meta-analysis to compare the efficacy and safety of docetaxel and pemetrexed or docetaxel and vinca alkaloid for non-small-cell lung cancer. This meta-analysis of Phase III randomized controlled trials was performed after searching PubMed, Embase, the Cochrane Library, and the ISI Web of Knowledge for randomized controlled trials. Outcome analyses were overall survival, progression-free survival, and overall response rate with 95% confidence intervals and major grade 3/4 toxicity. Seven eligible trials involving 2,080 patients were retrieved for analysis. Docetaxel enhanced progression-free survival and overall response rate compared with vinca alkaloid as first-line treatment (P<0.05). However, there was no difference between docetaxel and pemetrexed as both first-line and second-line treatment (P>0.05). With regard to the grade 3/4 toxicity, compared with pemetrexed, docetaxel led to higher neutropenia and febrile neutropenia (P<0.05), but there was no difference in non-hematological toxicity (P>0.05). Docetaxel led to a lower ra...Continue Reading
Citations
Feb 24, 2016·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Sun Min LimJoo-Hang Kim
Sep 24, 2016·Expert Review of Respiratory Medicine·A MatikasA Kotsakis
Dec 30, 2016·Medicine·Cuihua WangWei Wang
Nov 29, 2017·ESMO Open·Allan Ramos-EsquivelLuis Corrales-Rodríguez
Aug 18, 2018·BMJ Case Reports·Caren van RoekelTycho M T W Lock
Jan 11, 2019·Cancer Medicine·Zheng XuWenxiong Zhang
Sep 9, 2017·Oncotarget·Rui-Xue TangGang Chen
Sep 21, 2018·Oncoscience·Qingcheng DuZunnan Huang
Nov 5, 2019·Frontiers in Oncology·Elena PoddubskayaMadina Baranova
Jul 15, 2017·Scientific Reports·Jinxin ShiZhenning Wang
Jun 28, 2019·Nutrients·Dawid PrzystupskiJulita Kulbacka
Aug 10, 2017·Oncology Letters·Zulei LiHui Tian
Jan 29, 2019·Combinatorial Chemistry & High Throughput Screening·Chu-Hui Ru, Yan-Bing Zhuang
Oct 30, 2020·OncoTargets and Therapy·Tian-Hua Yue, Wei Xing
Jun 17, 2020·Toxicology and Applied Pharmacology·Peggy ArthurMandip Singh
Aug 28, 2021·International Journal of Molecular Sciences·Mi-So JeongSeong-Gyu Ko